|
Adoption rates of immune checkpoint inhibitors in real world oncology practice. |
|
|
Employment - Precision Health AI |
Leadership - Precision Health AI |
Stock and Other Ownership Interests - Precision Health AI; Transparency Life Sciences |
Consulting or Advisory Role - Transparency Life Sciences |
Research Funding - Precision Health AI |
|
|
Patents, Royalties, Other Intellectual Property - Philips Healthcare |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |
|
|
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |